Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1398.

https://doi.org/10.1182/blood-2018-99-114747

Published: 2018

Journal Articles

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Cannon Milani, MD, Rami Abumasmah, Ahmad-Samer Al-Homsi, MD

Blood (2009) 114 (22): 4303.

https://doi.org/10.1182/blood.V114.22.4303.4303

Published: 2009

Journal Articles

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Abir O. Kanaan, PharmD, Jennifer L. Donovan, PharmD, Paul P. Belliveau, PharmD, Tara Roy, NP, Ahmad-Samer Al-Homsi, MD

Blood (2006) 108 (11): 4126.

https://doi.org/10.1182/blood.V108.11.4126.4126

Published: 2006

Journal Articles

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Abir O. Kanaan, PharmD, Jennifer L. Donovan, PharmD, Matthew A. Silva, PharmD, Tara Roy, NP, Ahmad-Samer Al Homsi, MD

Blood (2006) 108 (11): 875.

https://doi.org/10.1182/blood.V108.11.875.875

Published: 2006

NARROW

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Email alerts

ASH Publications

American Society of Hematology

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Epstein-Barr Virus (EBV) Associated Post-Transplantation Lymphoproliferative Disorder Confined to the Central Nervous System Despite Negative Serum EBV PCR Following Rituxmab Administration.

Cost-Consequences of Fondaparinux Use for Treatment of Heparin-Induced Thrombocytopenia.

Venous Thromboembolism Prophylaxis in High Risk Medically Ill Patients; a Meta Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only